OSTX

0.80302.12%
RG

Robert G. Petit

Chief Medical Officer & Chief Scientific Officer

Dr. Robert G. Petit II, Ph.D., Serves as Senior Vice President of Early Clinical Development at Orionis Biosciences LLC. He serves as Chairman of Scientific Advisory Board of Advaxis, Inc. (now Ayala Pharmaceuticals, Inc.) since June 3, 2019. Dr. Petit serves as Chief Medical Officer and Chief Scientific Officer at OS Therapies Incorporated since September 2019. Dr. Petit has also served as Principal for RGP Biotech, LLC, where he advises clients on non-clinical and clinical development programs, since June 2019. He served as Senior Vice President, Head of Early Clinical Development for Orionis Biosciences Inc. He served as the Chief Scientific Officer of Advaxis, Inc. (now Ayala Pharmaceuticals, Inc.) since May 3, 2013 until June 3, 2019 and was its Executive Vice President since May 2013 until June 3, 2019. From June 2019 to December 2019, Dr. Petit served as the Chief Scientific Officer of Carisma Therapeutics, Inc. Dr. Petit joined Advaxis (now Ayala Pharmaceuticals, Inc.) in October 2010. Dr. Petit served as the Vice President of Clinical Operations and Medical Affairs at Advaxis, Inc. since October 11, 2010 until May 3, 2013. Dr. Petit joined Advaxis (now Ayala Pharmaceuticals, Inc.) from Bristol Myers Squibb where he served as the U.S. Medical Strategy Lead for the Ipilimumab program, Director of Medical Strategy for New Oncology Products and Director of Global Clinical Research from 2005 to 2010. Prior to joining Bristol Myers-Squibb, Dr. Petit served as Vice President of Clinical Development at MGI Pharma Inc and Aesgen Inc. He is also a member of the scientific advisory boards of Saros Therapeutics. His scientific focus has been to develop immunologic based therapies with a particular emphasis on immunologic oncology treatment. Dr. Petit has experience in all medical and scientific aspects of pharmaceutical development. Dr. Petit has led programs in discovery, translational development and intellectual property development and has designed and conducted U.S. and international clinical evaluation programs from phase I to IV. Dr. Petit served as a Director of Advaxis, Inc. (now Ayala Pharmaceuticals, Inc.) since July 26, 2016 until October 11, 2016. He is also a member of the scientific advisory boards of Systems Oncology, LLC. He has had significant FDA experience and has contributed to five NDA/BLA filings. Dr. Petit has a Doctorate from the Ohio State University College of Medicine and a B.S. from Indiana State University.

Positions